Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $16.18
  • 50 Day Moving Average: $15.01
  • 200 Day Moving Average: $20.14
  • 52-Week Range: $347,669,000.00 - $13.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.36
  • P/E Growth: 0.33
  • Market Cap: $5.63B
  • Outstanding Shares: 347,669,000
  • Beta: -0.17
  • Net Margins: -22.17%
  • Return on Equity: 43.81%
  • Return on Assets: 4.92%
  • Debt-to-Equity Ratio: 7.11%
  • Current Ratio: 1.46%
  • Quick Ratio: 1.12%
Additional Links:
Companies Related to Valeant Pharmaceuticals International:

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Ratings, 13 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: $30.23 (86.82% upside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateFirmActionRatingPrice TargetDetails
2/25/2017Wells Fargo & CoSet Price TargetSell$11.00View Rating Details
2/22/2017Canaccord GenuityReiterated RatingHold$19.00View Rating Details
2/16/2017MizuhoReiterated RatingUnderperform$11.00View Rating Details
2/14/2017Royal Bank of CanadaLower Price TargetSector Perform$29.00 -> $22.00View Rating Details
2/14/2017RBC Capital MarketsLower Price TargetSector Perform$29.00 -> $22.00View Rating Details
2/10/2017Barclays PLCLower Price TargetEqual Weight$34.00 -> $20.00View Rating Details
2/9/2017Stifel NicolausReiterated RatingBuy$45.00View Rating Details
2/7/2017GuggenheimReiterated RatingBuyView Rating Details
1/31/2017Rodman & RenshawDowngradeBuy -> NeutralView Rating Details
1/31/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
1/21/2017Deutsche Bank AGSet Price TargetHold$24.00 -> $20.00View Rating Details
1/11/2017BTIG ResearchReiterated RatingNeutralView Rating Details
12/14/2016Piper Jaffray CompaniesSet Price TargetSell$16.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal Weight$25.00 -> $17.00View Rating Details
11/10/2016ScotiabankReiterated RatingSector Perform$32.00 -> $17.00View Rating Details
11/10/2016BMO Capital MarketsReiterated RatingMarket Perform$21.00 -> $29.00View Rating Details
11/9/2016Jefferies Group LLCReiterated RatingBuy$40.00 -> $22.00View Rating Details
8/13/2016TD SecuritiesReiterated RatingBuy$38.00View Rating Details
5/29/2016Susquehanna Bancshares IncReiterated RatingHold$105.00View Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details
12/21/2015Bank of America CorpReiterated RatingBuyView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details
11/2/2015Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details
10/23/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416$1.21$2.34 billionN/AView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
Current Year EPS Consensus Estimate: $5.44 EPS
Next Year EPS Consensus Estimate: $4.81 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$1.21$1.21$1.21
(Data provided by Zacks Investment Research)


Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Ownership Percentage: 16.37%
Institutional Ownership Percentage: 64.34%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.00View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
News IconShare Performance and Target Price Review: Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (NYSE:VRX) - February 25 at 4:19 AM
News IconValeant Pharmaceuticals International, Inc. (VRX): Important Trade and Target Levels To Watch (NYSE:VRX) - February 25 at 4:19 AM logoThe Demise Of The Erectile Dysfunction TV Ads (NYSE:VRX) - February 24 at 9:17 AM logoValeant Pharmaceuticals Intl Inc’s (VRX) Obagi Medical Products Collaborates with Nextcell Medical to Bring New Line of Products (NYSE:VRX) - February 23 at 11:45 PM logoObagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products (NYSE:VRX) - February 23 at 11:45 PM logoFormer Valeant and Philidor execs plead not guilty in fraud scheme (NYSE:VRX) - February 23 at 11:45 PM
News IconValeant Pharmaceuticals International, Inc. (NYSE:VRX) Equity Price Target Fixed At $25.75 - Transcript Daily (NYSE:VRX) - February 23 at 3:21 AM logoStock Update (NYSE:VRX): Valeant Pharmaceuticals Intl Inc Signs Licensing Agreement with EyeGate - Smarter Analyst (NYSE:VRX) - February 21 at 4:06 PM logo​Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal (NYSE:VRX) - February 21 at 4:06 PM logoValeant Acquires Eyegate Licensing Rights (NYSE:VRX) - February 21 at 4:06 PM logoEyeGate Pharma surges 15% on news of Valeant licensing agreement - MarketWatch (NYSE:VRX) - February 21 at 8:14 AM logoValeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients (NYSE:VRX) - February 21 at 8:14 AM logoEyeGate Pharma surges 15% on news of Valeant licensing agreement (NYSE:VRX) - February 21 at 8:14 AM
News IconAnalysts Are Sizing Up Valeant Pharmaceuticals International, Inc. (NYSE:VRX): Where Does the Sell-Side See It Going? - Winfield Review (NYSE:VRX) - February 20 at 8:13 AM logoStocks to Watch: Kate Spade, MGM Resorts, Avon Products (NYSE:VRX) - February 18 at 7:31 PM logoValeant Pharmaceuticals: Dead in the Water? (NYSE:VRX) - February 18 at 7:31 PM logoNew Valeant Approval is a Surprise Irritant (NYSE:VRX) - February 18 at 7:31 PM logoWhy This FDA Approval for Valeant Is Not as Good as First Thought (NYSE:VRX) - February 18 at 7:31 PM
News IconEquity Watch: Looking at Shares of Valeant Pharmaceuticals International Inc. (VRX) - Baldwin Journal (NYSE:VRX) - February 17 at 5:06 PM logoFDA approves Valeant''s drug to treat plaque psoriasis - Nasdaq (NYSE:VRX) - February 17 at 5:06 PM logoIt Happened Again! Another Drugmaker Got Caught With an Exorbitant Price Hike (NYSE:VRX) - February 17 at 5:06 PM logoValeant's (VRX) Plaque Psoriasis Drug Approved in the U.S. (NYSE:VRX) - February 17 at 5:06 PM
News IconValeant Pharmaceuticals International, Inc. (NYSE:VRX) Sees Volume Pop in Session - Winfield Review (NYSE:VRX) - February 17 at 6:59 AM logoValeant stock surges 3% after psoriasis drug gets FDA approval - MarketWatch (NYSE:VRX) - February 17 at 6:59 AM logoValeant: Brodalumad Approval Won't End Woes - Seeking Alpha (NYSE:VRX) - February 17 at 6:59 AM
News IconStock Price of Valeant Pharmaceuticals International, Inc. (VRX) Increases 5.77% (NYSE:VRX) - February 15 at 1:57 AM logoVALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NYSE:VRX) - February 15 at 1:57 AM
News IconMost Active mover Update on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Winfield Review (NYSE:VRX) - February 14 at 8:52 PM logoAckman boosted Chipotle holdings, pared Valeant in 4th quarter (NYSE:VRX) - February 14 at 8:52 PM
News IconStock Drawing Back Today: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Aiken Advocate (NYSE:VRX) - February 14 at 3:50 PM
News IconImpact Score Of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) At 0 - Stock Observer (NYSE:VRX) - February 14 at 3:50 PM logoUpdate On Valeant's Debt Pathway After Asset Sales - Seeking Alpha (NYSE:VRX) - February 14 at 3:50 PM logoValeant: Why $3.75 Billion is the Most Important Number (NYSE:VRX) - February 14 at 3:50 PM
News IconInvestor View: Looking at Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Midway Monitor (NYSE:VRX) - February 14 at 6:58 AM logoShort Valeant For Brodalumab? - Seeking Alpha (NYSE:VRX) - February 11 at 6:15 AM
News IconValeant Pharmaceuticals International, Inc. (NYSE:VRX) Stock Price Target Given At $26.75 - Transcript Daily (NYSE:VRX) - February 10 at 6:33 AM logoValeant Pharmaceuticals: Worthy of Your Trust? (NYSE:VRX) - February 7 at 3:37 PM logoRuane, Cunniff & Goldfarb's Sequoia Fund 4th Quarter Shareholder Letter (NYSE:VRX) - February 7 at 3:37 PM logoWhy Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Finally Stabilize - (NYSE:VRX) - February 7 at 2:33 AM
News IconHap Trading LLC Has Lowered Its Valeant Pharmaceuticals Intl (Put) (VRX) Position as Stock Value Rose (NYSE:VRX) - February 2 at 6:40 AM
News IconTechnical Tracker: Watching Shares of Valeant Pharmaceuticals International Inc. (VRX.TO) - Rives Journal (NYSE:VRX) - January 31 at 2:16 AM
News IconThe Stock In Focus – Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Transcript Daily (NYSE:VRX) - January 31 at 2:16 AM logoValeant Pharmaceuticals: A Challenging Setup? (NYSE:VRX) - January 30 at 4:14 PM logoIs Valeant Pharmaceuticals' Turnaround Finally in the Cards? (NYSE:VRX) - January 30 at 4:14 PM logoValeant Pharmaceuticals Intl : The Valeant Pharmaceuticals International Inc. (Vrx) Position Lowered by Claren Road Asset Management Llc (NYSE:VRX) - January 30 at 9:59 AM
News IconROE of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stands at (NYSE:VRX) - January 28 at 2:01 AM
News IconThe Valeant Pharmaceuticals Intl's (VRX) Sector Perform Rating Reaffirmed at Scotiabank (NYSE:VRX) - January 28 at 2:01 AM logoBear of the Day: Valeant Pharmaceuticals (VRX) (NYSE:VRX) - January 28 at 2:01 AM
News IconEarnings in Full Force, Analysts Take Aim at Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Wall Street Beacon (NYSE:VRX) - January 27 at 3:49 PM
News IconSell-side Predictions for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Aiken Advocate (NYSE:VRX) - January 27 at 3:49 PM


What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?

23 equities research analysts have issued 12-month target prices for Valeant Pharmaceuticals International's shares. Their predictions range from $11.00 to $105.00. On average, they anticipate Valeant Pharmaceuticals International's stock price to reach $30.23 in the next year.

What are analysts saying about Valeant Pharmaceuticals International stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals International stock:

  • Wells Fargo & Co analysts commented, "On February 15, 2017, after the close, the FDA approved Valeant's Siliq (brodalumab). We believe that investors should sell Valeant shares on the news given 1) the stock is up 19% in the past five days (inclusive of afterhours) vs. +2.3% for the S&P500; 2) the approval is already assumed in consensus models; 3) the label is worse than expected; and 4) we believe the REMS program is an unexpected negative that will limit use. In addition, our new survey conducted this week of doctors who were not yet aware of a REMS was already showing a negative outlook for the drug. In this note we outline some of the findings from our survey this week. Respondents indicated that even if Siliq had been approved without a restrictive label, they would only prescribe it to approximately 7% of patients. We believe that with the label and REMS program, the actual use will be an even smaller fraction of patients." (2/16/2017)
  • RBC Capital Markets analysts commented, "Valeant will report Q4/16 results before markets open on February 28. We anticipate $2.37B in revenues, $1.05B in Adj. EBITDA, and $1.23 in Adj. EPS. We believe that the focus of VRX's Q4/16 release and conference call will be on 2017 guidance and how much lower it will be relative to 2016 results' Lowering price target to $22 largely owing to reduced derm outlook. Following our forecast revisions, our price target declines to $22 from $29. This is largely due to our lower derm forecast and weaker overall outlook. We have also lowered our EBITDA multiple from 8.25x to 8.0x, as we believe Valeant has heightened risk due to ongoing government investigations." (2/14/2017)
  • According to Zacks Investment Research, "Valeant’s lower-than-expected earnings in the second-quarter of 2016 were disappointing. Quarterly revenues were impacted by lower product sales from existing businesses and negative foreign exchange fluctuations. Valeant also incurred high R&D expenses due to development programs related to its dermatology portfolio, spending related to brodalumab, and programs acquired through the Salix acquisition. Nevertheless, the company has been active on the acquisition front over the last few years, which has been driving growth. Valeant’s efforts in venturing into the gastrointestinal disease & Women's Health Markets are also encouraging. However, Valeant has been in the spotlight since Aug 2015 for all the wrong reasons like a price hike of specialty drugs, erroneous financial reporting, and termination of contracts with Philidor Rx Services." (8/16/2016)

  • Jefferies Group LLC analysts commented, "VRX missed cons revs & EPS ests by 2% & 5% as the US derm/GI businesses remained sluggish. That said, EPS grew 10% Q/Q to reach $2.66 (39% of FY16 guidance). And there were some encouraging signs – with mgt delivering cost efficiencies, paying down another $880M in debt, selling modest sized non- core assets, deploying new initiatives to improve its derm/GI businesses, and offering a realistic pathway towards reaching debt obligations through 2017. 2016 Guidance Unchanged and It Remains Back Loaded; Can Mgt Deliver Despite Some Clear Headwinds?: Despite the Q2 miss relative to consensus, mgt maintained its full year rev & EPS guidance of $9.9-10.1B and $6.60-$7.00. Mgt cited 2H tailwinds from seasonality (e.g., derm), expectations of improved performance in US dermatology and GI following recent initiatives, front loaded R&D spend, and improved cost efficiencies as key reasons. Moreover, they expect to reach these targets despite the ongoing genericization of Ziana and Zegerid and likely loss of exclusivity to Nitropress in 4Q16." (8/10/2016)

  • Morgan Stanley analysts commented, "We provide perspectives on ten known unknowns and thoughts on Philidor investigations (details in body of report). When will it be safe to go back into the water? Will the 10-K be filed by the end April as planned? What will (and will not) be in the 10-K? What really happened at Philidor, and will there be 10-K disclosures beyond financial restatements? Why did the Valeant Board do a seemingly abrupt about-face on former CFO Howard Schiller, and how will the dispute be resolved? How will Valeant’s $31B debt burden be significantly relieved, and will there be dis-synergies? How will Valeant perform vs. guidance issued on March 15? Who will be the new CEO, and will that individual maintain guidance? How will Walgreens manage the conflict of interest between its Valeant deal and its partnerships with PBMs (e.g., OptumRx)? How will the payment of greater rebates impact 2017 US growth prospects? Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research." (3/28/2016)

Who owns Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock is owned by a number of of retail and institutional investors. Top institutional investors include Paulson & CO. Inc. (5.58%), Davis Selected Advisers (2.01%), Renaissance Technologies LLC (0.84%), FMR LLC (0.62%), Alyeska Investment Group L.P. (0.43%) and Saba Capital Management L.P. (0.29%). Company insiders that own Valeant Pharmaceuticals International stock include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Pavel Mirovsky, Pershing Square Capital Manage, Robert L Rosiello, Robert Roswell Chai-Onn, Ronald Harold Farmer and Thomas W Sr Ross.

Who sold Valeant Pharmaceuticals International stock? Who is selling Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Davis Selected Advisers, I.G. Investment Management LTD., Franklin Resources Inc., Scepter Holdings Inc., Fiera Capital Corp, Van ECK Associates Corp and AQR Capital Management LLC.

Who bought Valeant Pharmaceuticals International stock? Who is buying Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was purchased by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Renaissance Technologies LLC, City Financial Investment Co Ltd, Stonehill Capital Management LLC, Manikay Partners LLC, Folger Hill Asset Management LP, Arrowstreet Capital Limited Partnership and Saba Capital Management L.P.. Company insiders that have bought Valeant Pharmaceuticals International stock in the last two years include Anne Clem Whitaker, Argeris N Karabelas, Joseph C Papa, Robert L Rosiello, Ronald Harold Farmer and Thomas W Sr Ross.

How do I buy Valeant Pharmaceuticals International stock?

Shares of Valeant Pharmaceuticals International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Valeant Pharmaceuticals International stock cost?

One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately $16.18.

Valeant Pharmaceuticals International (NYSE:VRX) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Earnings History Chart

Earnings by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Dividend History Chart

Dividend Payments by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Last Updated on 2/27/2017 by Staff